An ACED Pilot Research Project

ELECTRIC: Early Detection of Hereditary Renal Cancer (RCC)

Lead 1: Dr Emma Woodward, University of Manchester

Lead 2: Dr Alice Fan, Stanford University

Lead 3: Prof Eamonn Maher, University of Cambridge


Project Summary

The number of cases of kidney cancer is increasing. When kidney cancer is found at an early-stage, patients can often be cured through early intervention. However, when kidney cancer is found at a stage where it has already spread throughout the body, which is the case in many non-hereditary cases, the chances of survival are often poor despite the availability of modern medical therapies. Studying hereditary kidney cancer is a good way to find and investigate markers, for example in the blood, that may allow for detecting kidney cancer earlier in both hereditary and non-hereditary cases. In this study, we will test if a candidate marker for early-stage kidney cancer that we have identified in the blood platelets of non-hereditary kidney cancer patients is also present in patients with hereditary kidney cancer. This will help to determine whether there are markers within the blood that are a realistic means to: (i) detect hereditary kidney cancer earlier, which currently requires costly and time-consuming repeat imaging, and; (ii) detect non-hereditary kidney cancer earlier, for which there is currently no screening test available.


Research Themes

Navigate back to read about the other Research Themes and projects

About ACED Manchester

ACED is a £55 million partnership between world-leading early detection institutes and organisations dedicated to improving the early detection of cancer.

Funding Opportunities

Discover the opportunities for ACED Member organisations to lever additional ACED funding in strategic areas.